QIAGEN expands digital PCR oncology research portfolio through partnership with ID Solutions
Partnership designed to expand QIAGEN’s leadership in oncology-focused digital PCR assays, advancing QIAcuity as the platform of choice for cancer research
Partnership designed to expand QIAGEN’s leadership in oncology-focused digital PCR assays, advancing QIAcuity as the platform of choice for cancer research
Discover AMSBIO’s optimized antibodies for stem cell research that offer high specificity, reproducibility, and validated purity for reliable results
Tecan experts share how to empower your lab by digitalizing the instruments and labware used in your workflows
The ORCA-Halo combines cutting-edge reliable technology with excellent image quality performance
A key focus of the partnership will be the development of adeno-associated virus gene therapy programs using intellectual property from KU Leuven
Waters has acquired Halo Labs™ to detect, identify, and count interfering materials (particles) in therapeutic products, such as cell, protein, and gene therapies
The new site is still within the Midlothian Science Zone and is now fully operational, marking a significant milestone in the company’s continued growth
Discover how prioritizing reproducibility and method validation can empower researchers to unlock the full potential of metabolomics in advancing biomarker discovery and drug development
The IDS i20 platform offers fully automated processing of specialty assays in endocrinology, allergy, autoimmune and infectious diseases, Alzheimer’s disease and therapeutic drug monitoring